ArticleScientific reports2025
Development and evaluation of deep neural networks for the classification of subtypes of renal cell carcinoma from kidney histopathology images.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A lightweight ResNet50V2-ECA model for renal cell carcinoma grading: efficiency, calibration, and state-of-the-art performance.Scientific reports · 2026Article
- A lightweight deep learning model with channel attention for kidney cell classification from microscopy images.Scientific reports · 2026Article
- Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.The Canadian journal of urology · 2026Review
- Automated Detection and Grading of Renal Cell Carcinoma in Histopathological Images via Efficient Attention Transformer Network.Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney cancer is a leading cause of cancer-related mortality, with renal cell carcinoma (RCC) being the most prevalent form, accounting for 80-85% of all renal tumors. Traditional diagnosis of kidney cancer requires manual examination and analysis of histopathology images, which is time-consuming, error-prone, and depends on the pathologist's expertise. Recently, deep learning algorithms have gained significant attention in histopathology image analysis. In this study, we developed an efficient and robust deep learning architecture called RenalNet for the classification of subtypes of RCC from kidney histopathology images. The RenalNet is designed to capture cross-channel and inter-spatial features at three different scales simultaneously and combine them together. Cross-channel features refer to the relationships and dependencies between different data channels, while inter-spatial features refer to patterns within small spatial regions. The architecture contains a CNN module called multiple channel residual transformation (MCRT), to focus on the most relevant morphological features of RCC by fusing the information from multiple paths. Further, to improve the network's representation power, a CNN module called Group Convolutional Deep Localization (GCDL) has been introduced, which effectively integrates three different feature descriptors. As a part of this study, we also introduced a novel benchmark dataset for the classification of subtypes of RCC from kidney histopathology images. We obtained digital hematoxylin and eosin (H&E) stained WSIs from The Cancer Genome Atlas (TCGA) and acquired region of interest (ROIs) under the supervision of experienced pathologists resulted in the creation of patches. To demonstrate that the proposed model is generalized and independent of the dataset, it has experimented on three well-known datasets. Compared to the best-performing state-of-the-art model, RenalNet achieves accuracies of 91.67%, 97.14%, and 97.24% on three different datasets. Additionally, the proposed method significantly reduces the number of parameters and FLOPs, demonstrating computationally efficient with 2.71 × [Formula: see text] FLOPs & 0.2131 × [Formula: see text] parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.